Dronabinol Erased PTSD Nightmares for Over a Third
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Dronabinol, a plant-derived THC medication given as evening drops, was tested in a randomized, double-blind, placebo-controlled trial of more than 170 PTSD patients at Charité - Universitätsmedizin Berlin, with results published in Nature Medicine.
- More than one-third of patients on Dronabinol reported their trauma-related nightmares disappeared completely after ten weeks, alongside an average 3.7-point drop in nightmare severity on an 8-point scale versus a 2.2-point drop in the placebo group.
- An additional 21% of Dronabinol patients saw their nightmare burden cut at least in half, and roughly five out of six in the treatment group felt their overall health had markedly improved, according to investigator Stefan Röpke.
- The benefit was specific to nightmares and sleep — the researchers could not conclusively show Dronabinol reduced overall PTSD severity or accompanying depression, the source notes.
- No severe side effects or withdrawal symptoms were reported; mild-to-moderate dizziness, headaches, and increased appetite were more common with Dronabinol, and no signs of dependence appeared after participants stopped the drug at study end.
- Germany currently has no approved medication specifically for trauma-related nightmares, and standard options like antidepressants and blood-pressure drugs offer limited relief — leaving this as the first trial aimed at that specific symptom in a rigorous design.
Why it matters: For PTSD patients whose lives are ruled by recurring trauma nightmares — and who in Germany have no approved medication targeting that specific symptom — Dronabinol produced complete nightmare cessation in over a third of participants in 10 weeks without severe side effects or withdrawal, offering the first evidence-backed pharmacological path to peaceful sleep for this patient group.
Ask SkimNews
